Care of persons with MS in clinical practice: Management by majority

The mid-1990s saw the advent of a new therapeutic era for multiple sclerosis (MS) with the approval of injectable disease-modifying therapies for relapsing-remitting MS. Despite some differences in routes of injection, frequency of administration, and adverse effects, the 4 initial therapies (interferon-β-1b, interferon-β-1a IM, interferon-β-1a subcutaneous, and glatiramer acetate) were remarkably similar in efficacy and generally safe. In the last 10 years, the landscape has changed dramatically. In addition to the initial 4 injectable therapies and new formulations of 2 of those therapies, 3 oral therapies and 3 infusion therapies are approved for use in relapsing forms of MS, excluding generics. In addition to differences in their routes of administration, these therapies differ importantly in their mechanisms of action, efficacy, and safety.
Source: Neurology Clinical Practice - Category: Neurology Authors: Tags: Multiple sclerosis Editorial Source Type: research